World Journal of
Pharmaceutical and Life Sciences

IN-VITRO EVALUATION OF CELL VIABILITY STUDIES OF NON-SMALL CELL LUNG CANCER USING SIMILAR MOLECULE - N-HYDROXY-OSIMERTINIB

Raheem Unnisa Shaik*, Dr. Syed Ahmed Hussain, Maimuna Fatima, Umaima Batool Osmani, Arshiya Tarannum, Faheem Unnisa and Nazneen

ABSTRACT

Aim: The study aims to investigate the cytotoxic effects of N-Hydroxy-osimertinib, a third-generation EGFR-TKI, on kidney cancer cells using various in vitro assays. Objective: The primary objective is to evaluate the efficacy of N-Hydroxy-osimertinib in reducing cell viability at different concentrations and compare its activity to Pembrolizumab, an established anti-PD-1 therapy for NSCLC. Research: Kidney cancer cells were treated with N-Hydroxy-osimertinib at concentrations of 1 μM, 5 μM, and 10 μM. The cytotoxic effects were assessed using MTT, CellTiter-Glo, Alamar Blue, SRB, and LDH Cytotoxicity assays. The results demonstrated a significant, dose-dependent decrease in cell viability across most assays, with cell viability dropping to 31.3% at 10 μM in the MTT assay. However, the LDH Cytotoxicity assay showed an increase in cell viability at 10 μM, suggesting potential alterations in cell membrane integrity or necrotic pathways at higher doses. Conclusion: N-Hydroxy-osimertinib exhibited potent anti-proliferative effects on kidney cancer cells, similar to or exceeding those of Pembrolizumab. While the compound shows promise as a potential therapeutic agent for NSCLC, further studies are needed to elucidate its mechanisms of action and validate its efficacy in preclinical and clinical settings.

[Full Text Article]   [Download Certificate]